BNT162b2 is a mRNA-based COVID-19 vaccine developed by BioNTech and Pfizer. It has been shown to be highly effective in preventing symptomatic COVID-19 infection in clinical trials, with an efficacy rate of over 90%. The vaccine works by introducing a small piece of the virus's genetic material into the body, which prompts the immune system to produce antibodies to fight off the virus. BNT162b2 has received emergency use authorization from regulatory agencies around the world and is being widely distributed as part of efforts to control the spread of the COVID-19 pandemic.